Vivek Jain, MD
Critical Care Medicine · Washington, DCNPI 1245249085
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (58.7%), food and beverage and education — rather than concentrated in one kind of arrangement. 18 manufacturers reported payments, led by ZOLL Respicardia, Inc. at 36.5% of the total. Reporting peaked in 2020 at $5,160 and has fallen 77.1% since, to $1,181 in 2025. Among critical care medicine clinicians in DC with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 64 payments — averaging $219.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ZOLL Respicardia, Inc.$5K
- Idorsia Pharmaceuticals US Inc$4K
- Inspire Medical Systems, Inc.$2K
- Jazz Pharmaceuticals Inc.$844
- Itamar Medical Inc$588
- Harmony Biosciences LLC$431
- plus $1K from 12 others
What the payments were for
- Speaking & faculty fees$8,25059%
- Travel & lodging$3112%
- Food & beverage$5,12636%
- Education$3583%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ZOLL Respicardia, Inc. | 2 | $5,128 |
| Idorsia Pharmaceuticals US Inc | 12 | $3,889 |
| Inspire Medical Systems, Inc. | 12 | $1,812 |
| Jazz Pharmaceuticals Inc. | 9 | $844 |
| Itamar Medical Inc | 3 | $588 |
| Harmony Biosciences LLC | 6 | $431 |
| Axsome Therapeutics, Inc. | 5 | $305 |
| Avadel CNS Pharmaceuticals, LLC | 2 | $228 |
| Boehringer Ingelheim | 2 | $188 |
| Grifols USA, LLC | 1 | $133 |
| Mylan Specialty L.p. | 1 | $119 |
| Philips North America LLC | 1 | $96 |
| Lilly USA, LLC | 3 | $96 |
| Insmed, Inc. | 1 | $96 |
| Fisher & Paykel Healthcare Inc | 1 | $35 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $30 |
| GSK | 1 | $15 |
| Carl Zeiss Meditec, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- remede System$5,128
- QUVIVIQ$3,595
- Inspire Upper Airway Stimulation System$1,061
- WatchPATONE$525
- Inspire$439
- XYWAV$268
- Wakix$243
- SUNOSI$227
- Prolastin-C Liquid$133
- LUMRYZ$118
How this compares
$14,045 in reported general payments places this provider in the 90th percentile of 59 critical care medicine providers in District of Columbia.
See all critical care medicine providers in District of Columbia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Modafinil | 15 | $1,151 |
| Zolpidem Tartrate | 15 | $236 |
Paid to pharmacies, not to this prescriber.
Other critical care medicine in Washington
- Lakhmir ChawlaWashington$441K
- Jonathan ChowWashington$285K
- Tunay KuruWashington$81K
- Kellen MulhernWashington$10K
- Jacob CollenWashington$8K
- Danielle DavisonWashington$5K
- Andrew HillWashington$5K
- Dina KianouryWashington$5K
- Brian LeeWashington$3K
- Pramod BhattaraiWashington$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.